AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2855297
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (80 micrograms per treatment, intranasally, three times daily for 5 days)
Trial: 11468426
Drug: d4T monotherapy
RxNorm normalized name: STAVUDINE (d4T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d4T monotherapy for 8 weeks
Trial: 31254201
Drug: Anthracycline-taxane-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-taxane-based chemotherapy (51.1% of deaths occurred here)
Trial: 29606226
Drug: S-Health smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Health smartphone application with daily surveys on cravings, affects, triggers, responses to triggers, and social contexts.
Trial: 29606226
Drug: Text messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messages from S-Health (e.g., HIV prevention and other educational materials).
Trial: 27352175
Drug: C18 (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C18 (18 mmol/l citrate solution)
Trial: 27352175
Drug: C15 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C15 (15 mmol/l citrate solution)
Trial: 25001621
Drug: Sufentanil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil administered intraoperatively and hydromorphone dosed postoperatively via target-controlled infusion (TCI) and patient-controlled analgesia (PCA) until 8 a.m. on the first postoperative day.
Trial: 16158800
Drug: Debridement and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement and short-term usage of antimicrobial agents
Trial: 12008938
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with melagatran and ximelagatran or dalteparin (exact dosage not specified)
Trial: 7568633
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg EtOH
Trial: 7568633
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg EtOH
Trial: 7568633
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg EtOH
Trial: 7568633
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg EtOH
Trial: 2332569
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing with individual components of Propine
Trial: 26246458
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/day plus saxagliptin and metformin
Trial: 26246458
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus saxagliptin and metformin
Trial: 22935227
Drug: Varicella vaccine
RxNorm normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varicella vaccine in SLE patients (28 vaccinated)
Trial: 11242149
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 300 mg twice a day until labour, 600 mg at the beginning of labour, and 300 mg twice a day for 7 days post-partum (n = 23)
Trial: 9586595
Drug: α‐adrenoceptor‐blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐adrenoceptor‐blockers
Trial: 9586595
Drug: 5‐α‐reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐α‐reductase inhibitors
Trial: 9586595
Drug: More uroselective
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More uroselective α‐blockers
Trial: 8147676
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (specific drugs not mentioned)
Trial: 8147676
Drug: Antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agents (general)
Trial: 23954313
Drug: CRF‐R1 antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRF‐R1 antagonist (GW876008) 20 mg or 200 mg
Trial: 23954313
Drug: CRF‐R1 antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRF‐R1 antagonist (GW876008)
Trial: 16542503
Drug: Oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate (1,600 mg/day)
Trial: 10741706
Drug: 45 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/m2 ATRA once daily
Trial: 10741706
Drug: 90 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/m2 ATRA once daily
Trial: 10741706
Drug: 150 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m2 ATRA once daily
Trial: 10741706
Drug: 15 mg/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/m2/day ATRA every 8 h
Trial: 10741706
Drug: ATRA pharmacokinetics
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA pharmacokinetics
Trial: 8463519
Drug: 24% protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% protein (61 g protein/L; n = 15)
Trial: 8463519
Drug: 14% protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14% protein (37 g protein/L; n = 13)
Trial: 3768576
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (one or more of a selection of individually tailored, cognitive‐behavioural therapies lasting an average of 9.1 sessions)
Trial: 3768576
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment (three or four sessions' assessment and advice)
Trial: 30298859
Drug: 1.23% acidulated
RxNorm normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% acidulated phosphate fluoride gel (APG)
Trial: 30298859
Drug: 2% neutral
RxNorm normalized name: Perfect Choice 2% Neutral Topical Gel (Vanilla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% neutral fluoride gel (NFG)
Trial: 26297933
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride gel (control); n = 153
Trial: 23661841
Drug: Combined supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplement of 40 mg zinc as zinc gluconate and 40 mg iron as ferrous sulphate
Trial: 23661841
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg elemental iron as ferrous sulphate (Control)
Trial: 17522789
Drug: Diclofenac low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac low-dose infusion
Trial: 12665701
Drug: Risedronate 30
RxNorm normalized name: risedronate 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 30 mg once weekly with vitamin D 400 iu daily and 1200 mg of calcium daily
Trial: 12665701
Drug: Risedronate 30
RxNorm normalized name: risedronate 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 30 mg once weekly
Trial: 29028788
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg every 3 weeks
Trial: 22336221
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m² every 21 days)
Trial: 16845252
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg plus Ramipril 2.5 mg daily
Trial: 14557145
Drug: High-frequency left-sided
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency left-sided repetitive transcranial magnetic stimulation (HFL-TMS) applied daily for 4 weeks (20 5-second trains at 10 Hz)
Trial: 14557145
Drug: Low-frequency right-sided
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency right-sided repetitive transcranial magnetic stimulation (LFR-TMS) applied daily for 4 weeks (five 60-second trains at 1 Hz)
Trial: 8883115
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg calcium as calcium citrate malate per day)
Trial: 8883115
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg calcium as calcium citrate malate per day) in subjects with above-median Tanner scores
Trial: 3880688
Drug: Indomethacin sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin sustained-release (ISR) oral preparation once a day at varying dosing times (8 a.m., noon, and 8 p.m.)
Trial: 3880688
Drug: Indomethacin sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin sustained-release (ISR) oral preparation at 8 a.m.
Trial: 3880688
Drug: Indomethacin sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin sustained-release (ISR) oral preparation at 8 p.m.
Trial: 3880688
Drug: Indomethacin sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin sustained-release (ISR) oral preparation with evening dosing
Trial: 3880688
Drug: Indomethacin sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin sustained-release (ISR) oral preparation with morning or noon dosing
Trial: 3880688
Drug: Indomethacin sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin sustained-release (ISR) oral preparation
Trial: 31136263
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP gel (3.5 ml ± 1.5 ml) injected at bone-tendon interface
Trial: 31136263
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PRP gel)
Trial: 25186834
Drug: Loading-dose rosuvastatin
RxNorm normalized name: omadacycline 7-Day Oral Pack incuding loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading-dose rosuvastatin 40 mg given 4 h before PCI
Trial: 25186834
Drug: Conventional-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose rosuvastatin 10 mg given 4 h before PCI
Trial: 20660279
Drug: Blueberry supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry supplementation (50 g freeze-dried blueberries, approximately 350 g fresh blueberries)
Trial: 20660279
Drug: Control (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (960 mL water)
Trial: 18778199
Drug: Peg‐Interferon alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐Interferon alpha‐2a (180 microg weekly subcutaneously)
Trial: 18778199
Drug: Peg‐Interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐Interferon alpha‐2b (1.5 microg/kg weekly subcutaneously)
Trial: 8896482
Drug: Iloprost regimen
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost regimen (intravenous at the beginning of the operation and three daily 6-hour infusions postoperatively, with an intragraft injection at completion of the bypass)
Trial: 2053784
Drug: Nebulised acidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised acidic salbutamol solution
Trial: 28677349
Drug: Anisodamine 10
RxNorm normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodamine 10 mg
Trial: 17287478
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg interleukin-12/23 monoclonal antibody
Trial: 17287478
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg interleukin-12/23 monoclonal antibody
Trial: 17287478
Drug: four weekly
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four weekly 45 mg interleukin-12/23 monoclonal antibody
Trial: 17287478
Drug: four weekly
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four weekly 90 mg interleukin-12/23 monoclonal antibody
Trial: 17287478
Drug: interleukin-12/23 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interleukin-12/23 monoclonal antibody
Trial: 3301120
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (SK) 1‐h infusion of 1,500,000 IU
Trial: 29314866
Drug: 900 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/day spearmint extract
Trial: 20110274
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment with follow-up visits to provide IDA education
Trial: 20110274
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment with no follow-up
Trial: 9692448
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of L-arginine administered during the first 30 minutes of cardioplegic arrest
Trial: 9692448
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-arginine supplementation)
Trial: 9692448
Drug: L-arginine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine group
Trial: 9692448
Drug: L-arginine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine group and control group
Trial: 20218011
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 2.9 and 16 min
Trial: 20218011
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 62 and 229 min
Trial: 20218011
Drug: All capsule
RxNorm normalized name: MemorAll Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All capsule formulations
Trial: 28956942
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ACT and WDI
Trial: 25808074
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine (15, 20, or 30 mg)
Trial: 29468446
Drug: Long-term temozolomide
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term temozolomide therapy
Trial: 29468446
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (short-term temozolomide)
Trial: 16969592
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg administered intravenously every 3 months
Trial: 8818849
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg azithromycin, administered orally once daily for 3 days
Trial: 8818849
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg roxithromycin, given orally twice daily for 10 days
Trial: 30118904
Drug: Hybrid light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid light activation (HL) with prior enamel acid etching (37% phosphoric acid for 15s) and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Trial: 30118904
Drug: Hybrid light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid light activation (HL) without prior enamel acid etching and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Trial: 30118904
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (GIII and IV) without HL, receiving 35% hydrogen peroxide gel (HP) applied for 3×15' without HL
Trial: 20846200
Drug: LEC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEC group - levofloxacin 500 mg, esomeprazole 40 mg, clarithromycin 500 mg once daily for 7 days
Trial: 20846200
Drug: AEC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEC group - amoxicillin 1 g, esomeprazole 40 mg, clarithromycin 500 mg twice daily for 7 days
Trial: 18223614
Drug: 26% dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26% dietary fat treatment
Trial: 18223614
Drug: 34% dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34% dietary fat treatment
Trial: 18223614
Drug: 40% dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% dietary fat treatment
Trial: 16565237
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 to 80 mg)
Trial: 10937427
Drug: Cough induced
RxNorm normalized name: Pediaclear Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cough induced with inhaled citric acid
Trial: 9017582
Drug: Cisplatin or
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin or carboplatin containing chemotherapy
Trial: 1460118
Drug: Isotretinoin cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin cream, applied once nightly for 36 weeks
Trial: 1460118
Drug: Vehicle cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream, applied once nightly for 36 weeks
Trial: 6381871
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.075 IU/kg)
Trial: 6381871
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (0.075 IU/kg)
Trial: 6381871
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.12 IU/kg)
Trial: 6381871
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (0.12 IU/kg)
Trial: 6381871
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin and Porcine insulin
Trial: 26875824
Drug: R-CHOP/R-CVP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP/R-CVP (standard therapy)
Trial: 17577041
Drug: FU-based combination
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU-based combination chemotherapy
Trial: 17577041
Drug: Gemcitabine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine combination chemotherapy
Trial: 7781622
Drug: Iatrogenic hypercortisolemia
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iatrogenic hypercortisolemia treatment for underlying diseases in pregnant women
Trial: 31453961
Drug: Ospemifene 60
RxNorm normalized name: ospemifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ospemifene 60 mg daily
Trial: 28658165
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy (invasive procedures such as endoscopic injection sclerotherapy or endoscopic band ligation) for esophageal varices
Trial: 16687711
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (88 mcg twice daily)
Trial: 8219947
Drug: Senna-fibre combination
RxNorm normalized name: senna glycosides, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna-fibre combination (10 ml daily)
Trial: 8219947
Drug: Lactulose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (15 ml twice daily)
Trial: 8219947
Drug: Senna-fibre combination
RxNorm normalized name: senna glycosides, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna-fibre combination
Trial: 3676920
Drug: L-Dopa (Sinemet)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-Dopa (Sinemet)
Trial: 29282600
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75 mg/m2 for 60 min at 43 °C
Trial: 27092908
Drug: Intranasal wide
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal wide dissection
Trial: 20520601
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg caffeine followed by 150 mg caffeine 90 min later
Trial: 20520601
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg and 150 mg)
Trial: 12704369
Drug: Long synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long synthetic overlapping peptides (LSP) immunotherapy, 100 microg per peptide, injected at days 0, 4, 7, 14, 42, and 70.
Trial: 1347267
Drug: Clemastine 2
RxNorm normalized name: clemastine 2 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 2 mg
Trial: 31496423
Drug: Community empowerment-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community empowerment-based model of combination HIV prevention